Show
Sort by
-
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age
(2022) HIV MEDICINE. -
- Journal Article
- A1
- open access
Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV aged ≥ 65 years : week 48 results of a phase 3b, open-label trial
-
Clinical characteristics and outcomes of COVID‐19 in people living with HIV in Belgium : a multicenter, retrospective cohort
-
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response : a sub-study of the NEAT001/ANRS143 randomized trial
-
- Journal Article
- A1
- open access
Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription
-
Relationship between HIV-1 env sequences from rebound plasma virus and viral outgrowth
-
Analytical treatment interruption (ATI) in patients with very small HIV reservoir
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
-
- Journal Article
- A1
- open access
Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium : a multicenter, retrospective study
-
- Journal Article
- A1
- open access
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study